ClinicalTrials.gg
TerminatedNCT03205046Updated Jan 6, 2021Results posted

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

A Phase 1/2 interventional study of acalabrutinib and vistusertib in DLBCL and Richter Syndrome, sponsored by Acerta Pharma BV. Terminated at 11 sites in 2 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-01-06.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Sponsor's decision not to pursue further development of the combination in DLBCL

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Study summary

This study evaluates the safety of acalabrutinib and vistusertib when taken in combination.

02

Conditions studied

  • DLBCL
  • Richter Syndrome
03

In context

Lead sponsor

Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.

First submitted after Acerta Pharma BV became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of diffuse large B-cell lymphoma (DLBCL) as documented by medical records and with histology based on criteria established by The World Health Organization (WHO):

    • If a subject has de novo DLBCL, the diagnosis is confirmed by and is immunohistologically characterized as de novo germinal center B-cell-like (GCB) DLBCL or de novo non-GCB DLBCL.
    • If the subjects has Richter's Syndrome (RS), the diagnosis is confirmed by biopsy and is immunohistologically characterized as transformation to DLBCL.
    • If the subjects has transformed DLBCL, the diagnosis is confirmed by biopsy and is immunohistologically characterized as transformation to DLBCL from indolent lymphoma (eg, follicular lymphoma).
  2. Men and women ≥18 years of age.
  3. Prior treatment for lymphoid :

    • If the subject has DLBCL, there is no curative option with conventional therapy and the prior treatment included ≥ 1 prior combination chemoimmunotherapy regimen.
    • If the subject has RS, the subject must have had ≥1 prior treatment with a combination chemoimmunotherapy regimen.
  4. (ECOG) performance status of ≤2.
  5. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of a ≥1.5 cm lesion, as measured in the longest dimension by computed tomography [CT] scan).

Exclusion criteria

Exclusion Criteria:

  1. As judged by the Investigator, any evidence of severe or uncontrolled systemic disease (eg, severe hepatic impairment, interstitial lung disease [bilateral, diffuse, parenchymal lung disease]), or current unstable or uncompensated respiratory or cardiac conditions, or uncontrolled hypertension, history of, or active, bleeding diatheses (eg, hemophilia or von Willebrand disease) or uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti-infective treatment within 2 weeks before first dose of study drug.
  2. Diagnosis of PMBCL.
  3. Current nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  4. History of central nervous system (CNS) lymphoma, or spinal cord compression.
  5. Any pre-existing severe renal disease (eg, glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis) or high risk of developing severe renal impairment.
  6. Abnormal echocardiogram (ECHO) or multi-gated acquisition scan () at baseline (left ventricular ejection fraction [LVEF] \<40% and shortening fraction \<15%). Appropriate correction to be used, if a MUGA is performed.
  7. Mean resting interval (QTc) calculated using Fridericia's formula (QTcF) >450 msec obtained from 3 (ECGs); family or personal history of long or short QT syndrome; Brugada syndrome or known history of QTc prolongation or torsade de pointes within 12 months of the subject entering the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Part 1 continuous dose for vistusertib

    acalabrutinib daily + vistusertib daily

    Drug: acalabrutinib · Drug: vistusertib

  • Experimental
    Part 1 intermittent dose for vistusertib

    acalabrutinib daily + vistusertib 5 days on and 2 days off

    Drug: acalabrutinib · Drug: vistusertib

Interventions

  • Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.

    Also known as: ACP-196

  • Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase

    Also known as: AZD2014

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs)

    Safety assessments comprised type, frequency, severity, and relationship to either or both study drug of any AEs or abnormalities of laboratory tests; serious adverse events (SAEs); dose-limiting toxicities (DLTs); or AEs that led to dose modification, dose delay, or discontinuation of study drug(s).

    Time frame: From first dose of study drug until 30 days post last dose

07

Results

Posted Jan 6, 2021
Limitations and caveats
Enrollment to this study was stopped early by the sponsor and an abbreviated CSR was generated.

Participant flow

Participant flow — Overall Study
MilestoneAcalabrutinib 100 mg BID Plus Vistusertib BID ContinuousAcalabrutinib 100 mg BID Plus Vistusertib BID Intermittent
Started1312
Completed02
Not completed1310
Withdrew: Death106
Withdrew: Withdrawal by subject12
Withdrew: Lost to follow-up01
Withdrew: Study terminated by sponsor21

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs)

Safety assessments comprised type, frequency, severity, and relationship to either or both study drug of any AEs or abnormalities of laboratory tests; serious adverse events (SAEs); dose-limiting toxicities (DLTs); or AEs that led to dose modification, dose delay, or discontinuation of study drug(s).

Time frame:
From first dose of study drug until 30 days post last dose
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs)
ParticipantsAcalabrutinib 100 mg BID* Plus Vistusertib BID* ContinuousAcalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent
Number of Participants With Treatment-Emergent Adverse Events (AEs)1312

Adverse events

Collected over Serious Adverse Events and Other Adverse Events were assessed from first dose of study drug until 30 days post last dose; All-Cause Mortality was assessed from first dose of study drug until death, loss to follow up, sponsor decision to stop trial, or withdrawal of consent, whichever occurred first, an average of approximately 6 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acalabrutinib 100 mg BID* Plus Vistusertib BID* Continuous10/13 (76.9%)2/13 (15.4%)13/13 (100%)
Acalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent6/12 (50%)6/12 (50%)12/12 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventAcalabrutinib 100 mg BID* Plus Vistusertib BID* ContinuousAcalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent
AnaemiaBlood and lymphatic system disorders0/132/12
PneumoniaInfections and infestations0/132/12
Lymph node painBlood and lymphatic system disorders0/131/12
AstheniaGeneral disorders0/131/12
PyrexiaGeneral disorders1/131/12
Lower respiratory tract infectionInfections and infestations0/131/12
Computerised tomogram thorax abnormalInvestigations0/131/12
Pain in extremityMusculoskeletal and connective tissue disorders0/131/12
SyncopeNervous system disorders0/131/12
Trigeminal neuralgiaNervous system disorders0/131/12
Most frequent other events
Showing 10 of 116
Most frequent other events
EventAcalabrutinib 100 mg BID* Plus Vistusertib BID* ContinuousAcalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent
NauseaGastrointestinal disorders1/138/12
FatigueGeneral disorders4/138/12
Blood creatinine increasedInvestigations4/137/12
ConstipationGastrointestinal disorders0/136/12
Decreased appetiteMetabolism and nutrition disorders0/136/12
DiarrhoeaGastrointestinal disorders6/132/12
AnaemiaBlood and lymphatic system disorders2/135/12
VomitingGastrointestinal disorders1/135/12
HyperglycaemiaMetabolism and nutrition disorders3/135/12
HypotensionVascular disorders0/135/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Acalabrutinib 100 mg BID* Plus Vistusertib BID* ContinuousAcalabrutinib 100 mg BID* Plus Vistusertib BID* IntermittentTotal
Mean63.6 ± 15.967.3 ± 12.065.4 ± 13.99
Sex: Female, Male
Sex: Female, Male(Participants)Acalabrutinib 100 mg BID* Plus Vistusertib BID* ContinuousAcalabrutinib 100 mg BID* Plus Vistusertib BID* IntermittentTotal
Female426
Male91019
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Acalabrutinib 100 mg BID* Plus Vistusertib BID* ContinuousAcalabrutinib 100 mg BID* Plus Vistusertib BID* IntermittentTotal
Hispanic or Latino011
Not Hispanic or Latino111122
Unknown or Not Reported202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Acalabrutinib 100 mg BID* Plus Vistusertib BID* ContinuousAcalabrutinib 100 mg BID* Plus Vistusertib BID* IntermittentTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White121123
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)Acalabrutinib 100 mg BID* Plus Vistusertib BID* ContinuousAcalabrutinib 100 mg BID* Plus Vistusertib BID* IntermittentTotal
United States5914
United Kingdom8311
08

Study locations

11 sites
  • Research Site
    Fairway, Kansas 66205, United States
  • Research Site
    Bethesda, Maryland 20892, United States
  • Research Site
    Rochester, Minnesota 55902, United States
  • Research Site
    Omaha, Nebraska 68198, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Seattle, Washington 98109, United States
  • Research Site
    Headington, OX3 7LJ, United Kingdom
  • Research Site
    London, EC1A 7BE, United Kingdom
  • Research Site
    Nottingham, NG5 1PB, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Collins GP, Clevenger TN, Burke KA, Yang B, MacDonald A, Cunningham D, Fox CP, Goy A, Gribben J, Nowakowski GS, Roschewski M, Vose JM, Vallurupalli A, Cheung J, Raymond A, Nuttall B, Stetson D, Dougherty BA, Schalkwijk S, Carnevalli LS, Willis B, Tao L, Harrington EA, Hamdy A, Izumi R, Pease JE, Frigault MM, Flinn I. A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. Leuk Lymphoma. 2021 Nov;62(11):2625-2636. doi: 10.1080/10428194.2021.1938027. Epub 2021 Jul 16. PubMed 34269152 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Nov 2019, 28 months.

Results were first posted in Jan 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2017
First posted
Jul 2, 2017
StartActual
Jun 29, 2017
Primary completionActual
Nov 20, 2019
CompletionActual
Nov 20, 2019
Results first posted
Jan 6, 2021
Last update
Jan 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03205046
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Jul 2, 2017
Start date
Jun 29, 2017
Primary completion
Nov 20, 2019
Completion
Nov 20, 2019
Results posted
Jan 6, 2021
Last update
Jan 6, 2021

Study contacts

Acerta Clinical Trials
study director · 1-888-292-9613; acertamc@dlss.com

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acalabrutinib · Vistusertib

Start the discussion